Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Core Insights - Myriad Genetics is presenting new data at the 2026 ASCO-GU conference that emphasizes its expanding role in cancer care through its molecular diagnostic tests, including the Precise MRD Test, Prolaris Prostate Cancer Prognostic Test, and MyRisk Hereditary Cancer Tests [1][8] Group 1: Precise MRD Test - The Precise MRD Test demonstrates high sensitivity in detecting molecular residual disease in genitourinary cancers, with detection events occurring at ctDNA concentrations below 100 parts per million [2] - Early evidence suggests a correlation between ctDNA levels and clinical outcomes, indicating the test's potential to provide clinically significant information [2] Group 2: Prolaris Prostate Cancer Prognostic Test - A robust meta-analysis of 14 studies involving over 8,000 patients supports the prognostic power of the Prolaris Test, showing significant prognostic value for distant metastasis and prostate-cancer specific mortality [3] - Prolaris is found to be prognostic beyond conventional risk categories based solely on clinical factors, aiding in initial treatment decisions [3] Group 3: MyRisk Hereditary Cancer Test - Data presented on the MyRisk Test indicate that germline positivity rates do not significantly differ across Gleason score and NCCN risk groups, suggesting that germline testing should not be limited to high-risk patients [4] - The findings may broaden the scope of individuals who could benefit from genetic testing in localized prostate cancer [4] Group 4: Conference Details - Myriad Genetics will exhibit at the ASCO-GU conference from February 26-28, 2026, at the Moscone West Conference Center in San Francisco, showcasing its latest research and findings [5][6]